侵袭性复发性呼吸道乳头状瘤病：连续5例患者接受辅助性静脉注射贝伐单抗治疗成功。比利时单一学术中心的经验。
Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.
作者信息
Collette Fanny, Lawson Georges, Hassid Samantha, Delahaut Gilles, Bachy Vincent, Van Der Vorst Sébastien, Faugeras Laurence, Gilliaux Quentin, D'Hondt Lionel
机构信息
Department of Oncology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
Department of ENT and Head and Neck Surgery, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
出版信息
Head Neck. 2023 May;45(5):1071-1079. doi: 10.1002/hed.27300. Epub 2023 Feb 25.
BACKGROUND
Recurrent respiratory papillomatosis (RRP) is a currently incurable benign neoplasm caused by human papilloma virus (HPV) infection. It usually reduces voice, respiratory, and general quality of life, and is sometimes life-threatening. Patients usually need repeated operations. The use of adjuvant bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, has been described in several case reports, with a good efficacy and safety profile.
METHODS
We report the cases of five patients with aggressive RRP who were treated with adjuvant systemic bevacizumab in a single Belgian tertiary center.
RESULTS
A complete response was achieved in four patients after a median of 4.5 months, and a partial response in one. In all cases, the number of surgeries was drastically reduced, and quality of life improved. Toxicity was easily managed.
CONCLUSIONS
Systemic bevacizumab seems to be an effective and safe adjuvant treatment for aggressive RRP.
背景
复发性呼吸道乳头状瘤病（RRP）是一种目前无法治愈的良性肿瘤，由人乳头瘤病毒（HPV）感染引起。它通常会降低嗓音、呼吸功能及总体生活质量，有时甚至危及生命。患者通常需要反复手术。在一些病例报告中描述了使用贝伐单抗（一种靶向血管内皮生长因子A的单克隆抗体）作为辅助治疗，其疗效和安全性良好。
方法
我们报告了在比利时一家三级中心接受贝伐单抗辅助全身治疗的5例侵袭性RRP患者的病例。
结果
4例患者在中位4.5个月后实现完全缓解，1例部分缓解。在所有病例中，手术次数大幅减少，生活质量得到改善。毒性易于控制。
结论
全身应用贝伐单抗似乎是侵袭性RRP一种有效且安全的辅助治疗方法。
Zotero 插件